Previous close | 133.49 |
Open | 133.08 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 131.05 - 133.91 |
52-week range | 55.68 - 155.48 |
Volume | |
Avg. volume | 424 |
Market cap | 108.737M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript May 1, 2024 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.37, expectations were $-0.11. Sarepta Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome […]
Q1 2024 Sarepta Therapeutics Inc Earnings Call